DAWN · Categories · Form 4

DAWN - SEC Form 4 insider transactions

Day One Biopharmaceuticals Inc. (DAWN) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for DAWN

• 42d
  SEC Form 4 filed by Large owner Ai Day1 Llc

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 46d
  CHIEF EXECUTIVE OFFICER Bender Jeremy returned 1,799,031 shares to the company, closing all direct ownership in the company (SEC Form 4) (for withholding tax)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 46d
  Head of Research and Dev. Vasconcelles Michael returned 4,397 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 46d
  COO and CFO York Charles N Ii returned 312,025 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 46d
  Gen Counsel & Secretary Dubow Adam returned 72,694 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 46d
  Director Holles Natalie C. returned 57,310 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy tax liability

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 46d
  Director Ramasastry Saira returned 40,485 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 46d
  Director Josey John A. returned 72,292 shares to the company, closing all direct ownership in the company (SEC Form 4) (for withholding tax)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 46d
  SEC Form 4 filed by Director Garland J. Scott (withholding tax)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 46d
  SEC Form 4 filed by Director Dable Habib J to cover withholding tax

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 46d
  SEC Form 4 filed by Director Grossman William to satisfy withholding tax

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 46d
  SEC Form 4 filed by Director Nicholson Garry A to satisfy withholding tax

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 46d
  Chief Commercial Officer Merendino Lauren returned 60,157 shares to the company, closing all direct ownership in the company (SEC Form 4) (for tax liability)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 110d
  Chief Commercial Officer Merendino Lauren converted options into 15,162 shares and sold $67,448 worth of shares (5,814 units at $11.60), increasing direct ownership by 18% to 60,157 units (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 110d
  Gen Counsel & Secretary Dubow Adam converted options into 16,463 shares and sold $74,188 worth of shares (6,395 units at $11.60), increasing direct ownership by 16% to 72,694 units (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 110d
  COO and CFO York Charles N Ii converted options into 23,375 shares and sold $70,359 worth of shares (6,065 units at $11.60), increasing direct ownership by 6% to 312,025 units (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 110d
  CHIEF EXECUTIVE OFFICER Bender Jeremy converted options into 42,937 shares and sold $179,338 worth of shares (15,459 units at $11.60), increasing direct ownership by 15% to 204,603 units (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 110d
  Head of Research and Dev. Vasconcelles Michael converted options into 7,125 shares and sold $31,647 worth of shares (2,728 units at $11.60) (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 129d
  SEC Form 4 filed by COO and CFO York Charles N Ii

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 129d
  SEC Form 4 filed by Head of Research and Dev. Vasconcelles Michael

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 129d
  SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Bender Jeremy

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 129d
  SEC Form 4 filed by Chief Commercial Officer Merendino Lauren

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 129d
  SEC Form 4 filed by Gen Counsel & Secretary Dubow Adam

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 194d
  CHIEF EXECUTIVE OFFICER Bender Jeremy received a gift of 600,000 shares and gifted 614,450 shares (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 202d
  Gen Counsel & Secretary Dubow Adam converted options into 12,087 shares and sold $38,503 worth of shares (4,319 units at $8.91), increasing direct ownership by 14% to 62,626 units (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 202d
  COO and CFO York Charles N Ii converted options into 16,875 shares and sold $36,212 worth of shares (4,062 units at $8.91), increasing direct ownership by 5% to 294,715 units (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 202d
  Chief Commercial Officer Merendino Lauren converted options into 10,536 shares and sold $33,216 worth of shares (3,726 units at $8.91), increasing direct ownership by 15% to 50,809 units (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 202d
  CHIEF EXECUTIVE OFFICER Bender Jeremy sold $141,690 worth of shares (15,894 units at $8.91) and converted options into 31,694 shares, increasing direct ownership by 10% to 177,165 units (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 213d
  SEC Form 4 filed by Director Dable Habib J

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 213d
  SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Bender Jeremy

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 213d
  SEC Form 4 filed by Director Josey John A.

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 213d
  SEC Form 4 filed by Director Holles Natalie C.

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 213d
  SEC Form 4 filed by Director Nicholson Garry A

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 213d
  SEC Form 4 filed by Director Garland J. Scott

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 213d
  SEC Form 4 filed by Director Ramasastry Saira

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 213d
  SEC Form 4 filed by COO and CFO York Charles N Ii

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 213d
  SEC Form 4 filed by Gen Counsel & Secretary Dubow Adam

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 213d
  SEC Form 4 filed by Director Grossman William

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 213d
  SEC Form 4 filed by Chief Commercial Officer Merendino Lauren

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 293d
  COO and CFO York Charles N Ii converted options into 16,875 shares and sold $27,786 worth of shares (4,106 units at $6.77), increasing direct ownership by 5% to 278,000 units (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 293d
  Gen Counsel & Secretary Dubow Adam converted options into 12,087 shares and sold $29,538 worth of shares (4,365 units at $6.77), increasing direct ownership by 16% to 54,858 units (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 293d
  CHIEF EXECUTIVE OFFICER Bender Jeremy converted options into 31,686 shares and sold $108,666 worth of shares (16,058 units at $6.77), increasing direct ownership by 11% to 161,365 units (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 293d
  Chief Commercial Officer Merendino Lauren converted options into 10,536 shares and sold $25,485 worth of shares (3,766 units at $6.77), increasing direct ownership by 19% to 41,931 units (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 329d
  CHIEF EXECUTIVE OFFICER Bender Jeremy gifted 601,259 shares and received a gift of 601,259 shares (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 355d
  SEC Form 4 filed by Head of Research and Dev. Vasconcelles Michael

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 369d
  SEC Form 4 filed by Director Grossman William

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 369d
  SEC Form 4 filed by Director Dable Habib J

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 369d
  SEC Form 4 filed by Director Ramasastry Saira

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 369d
  SEC Form 4 filed by Director Garland J. Scott

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 369d
  SEC Form 4 filed by Director Nicholson Garry A

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 369d
  SEC Form 4 filed by Director Holles Natalie C.

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 369d
  SEC Form 4 filed by Director Josey John A.

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 385d
  Chief Commercial Officer Merendino Lauren converted options into 10,536 shares and sold $24,575 worth of shares (3,927 units at $6.26), increasing direct ownership by 23% to 35,161 units (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 385d
  GENERAL COUNSEL Dubow Adam converted options into 12,086 shares and sold $28,486 worth of shares (4,552 units at $6.26), increasing direct ownership by 19% to 47,136 units (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 385d
  COO, CFO AND SECRETARY York Charles N Ii converted options into 16,875 shares and sold $26,796 worth of shares (4,282 units at $6.26), increasing direct ownership by 5% to 265,231 units (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 385d
  CHIEF EXECUTIVE OFFICER Bender Jeremy converted options into 31,686 shares and sold $87,385 worth of shares (13,964 units at $6.26), increasing direct ownership by 14% to 145,737 units (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 472d
  COO, CFO AND SECRETARY York Charles N Ii converted options into 16,875 shares and sold $52,278 worth of shares (4,370 units at $11.96), increasing direct ownership by 5% to 252,638 units (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 472d
  GENERAL COUNSEL Dubow Adam converted options into 12,086 shares and sold $55,580 worth of shares (4,646 units at $11.96), increasing direct ownership by 23% to 39,602 units (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 472d
  CHIEF EXECUTIVE OFFICER Bender Jeremy converted options into 31,686 shares and sold $144,130 worth of shares (12,048 units at $11.96), increasing direct ownership by 18% to 128,015 units (SEC Form 4)

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
• 493d
  SEC Form 4 filed by COO, CFO AND SECRETARY York Charles N Ii

  4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

Other DAWN categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends